Novo Nordisk A/S (NVO) vs Pfizer Inc. (PFE)
A side-by-side comparison of Novo Nordisk A/S and Pfizer Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of August 1, 2026. Differences are shown without an overall score or investment verdict.
NVO
Novo Nordisk A/S
$47.08HealthcareAt close: Jul 31, 2026, 4:00 PM ET
PFE
Pfizer Inc.
$25.01HealthcareAt close: Jul 31, 2026, 4:00 PM ET
Total return — NVO vs PFE
growth of $100 · dividends reinvested · last 30yNVO +10806.6%PFE +555.6%NVO compounded faster
Log scale — wide-divergence pair
NVO PFE
NVO vs PFE: by the numbers
- •NVO is the larger company ($209.19B vs $142.54B market cap).
- •NVO trades at the lower trailing earnings multiple (11.01 vs 19.09 P/E), one valuation lens rather than an overall verdict.
- •NVO converts more revenue to profit (37.14% vs 11.83% net margin).
- •NVO grew revenue faster over the past five years (20.73% vs 8.22% CAGR).
- •PFE pays the higher dividend yield (6.88% vs 3.83%).
Metrics side by side
Valuation
| Metric | NVO | PFE |
|---|---|---|
| P/E ratio | 11.01 | 19.09 |
| Forward P/E | N/A | 8.50 |
| P/S ratio | 4.09 | 2.26 |
| P/B ratio | 6.69 | 1.59 |
| PEG ratio | 8.16 | N/A |
| EV / EBITDA | 8.62 | 9.81 |
| FCF yield | 2.31% | 6.62% |
Profitability
| Metric | NVO | PFE |
|---|---|---|
| Gross margin | 81.83% | 69.35% |
| Operating margin | 45.21% | 23.45% |
| Net margin | 37.14% | 11.83% |
| ROE | 60.74% | 8.31% |
| ROIC | 29.53% | 8.84% |
Dividends
| Metric | NVO | PFE |
|---|---|---|
| Dividend yield | 3.83% | 6.88% |
| Payout ratio | 49.80% | 126.47% |
Growth (annualized)
| Metric | NVO | PFE |
|---|---|---|
| Revenue CAGR (5Y) | 20.73% | 8.22% |
| EPS CAGR (5Y) | 19.59% | -3.78% |
| FCF CAGR (5Y) | -5.86% | -3.79% |
| Total return CAGR (5Y) | 2.46% | -5.29% |
Frequently asked
- Which has the lower trailing P/E, NVO or PFE?
- NVO has the lower trailing P/E: NVO trades at 11.01 and PFE at 19.09. P/E is one valuation measure and does not by itself establish which business is cheaper.
- Which has grown faster, NVO or PFE?
- Over the past five years, NVO grew revenue faster — NVO at a 20.73% CAGR versus PFE at 8.22%.
- Does NVO or PFE pay a bigger dividend?
- NVO yields 3.83% and PFE yields 6.88% based on trailing dividends and the latest price.
- Is NVO or PFE more profitable?
- NVO runs the higher net margin — NVO at 37.14% versus PFE at 11.83%.
- How have NVO and PFE total returns compared?
- Over the past 10 years, NVO delivered 7.59% and PFE delivered 1.38% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Novo Nordisk A/S P/E ratioPfizer P/E ratioNovo Nordisk A/S dividend yieldPfizer dividend yieldNovo Nordisk A/S ROEPfizer ROENovo Nordisk A/S operating marginPfizer operating marginNovo Nordisk A/S revenue growthPfizer revenue growthNovo Nordisk A/S free cash flowPfizer free cash flow
Novo Nordisk A/S & Pfizer appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified August 1, 2026.